Good run continues for Imugene with $1.85M R&D tax incentive
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical-stage immuno-oncology company, Imugene (ASX:IMU), has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme.
The receipt of the $1.85 million in additional funding will go towards IMU’s commercial and clinical milestones, with the company experiencing its most significant period of R&D expenditure in the September 2018 quarter — when R&D outflows totalled $1.65 million.
The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.
The Australian government’s R&D tax incentive encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% for eligible activities.
IMU has a highly experienced leadership team, including Chairperson Paul Hopper — who led small cap Viralytics to a $502.4 million buyout by pharmaceutical giant, Merck & Co (NYSE:MRK) earlier this year.
In June this year, IMU signed an exclusive world-wide licence for the entire body of cancer vaccine work and intellectual property developed by Professor Pravin Kaumaya of the Ohio State University Wexner Medical Centre and Dr Tanios Bekaii Saab of the Mayo Clinic.
The deal transforms IMU’s position from a one product, one-trial focused small cap to a substantial intellectual property estate. In total, it now holds six patent families, comprising 16 patents or pending applications for a large range of B-cell peptide and cancer vaccines.
IMU’s flagship HER-Vaxx drug candidate is currently in Phase I/b, with results expected in the near-term.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
